The company will stop testing the drug, magrolimab, for all blood cancers and will review its safety across other studies such as those in patients with colon and breast cancers. Gilead gained access to the drug through its $4.9 billion purchase of Forty Seven Inc in 2020. An analysis of a late-stage trial and other studies showed an increased risk of death, the company said, adding it also showed that the drug was unlikely to succeed in the trials.
Related Keywords
Bengaluru , Karnataka , India , Sriraj Kalluvila , Khushi Mandowara , Drug Administration , Reuters , Gilead Sciences , Blood Cancer , Food And Drug Administration , Patient Death ,
vimarsana.com © 2020. All Rights Reserved.